PENN II — BRCA1/2 Mutation Probability Score

Why use it

Provides a rapid, validated, externally applicable tool for point-of-care screening of patients who should be referred for BRCA1/2 genetic counseling. Does not require specialized software or complex pedigree modeling. Widely used in primary care, gynecology, and oncology settings. Validated against BRCAPRO in multiple independent cohorts. Useful for insurance pre-authorization documentation.

About

The PENN II Risk Model is a validated, point-based clinical scoring system that estimates the prior probability that an individual carries a germline pathogenic variant in BRCA1 or BRCA2. It utilizes personal and family history of breast, ovarian, and related cancers to generate a weighted score. A score of ≥ 10 is widely accepted as indicating a ≥ 10% prior probability of carrying a BRCA1/2 mutation — the conventional threshold justifying referral for genetic counseling and consideration of genetic testing. Unlike probability-model tools (BRCAPRO, BOADICEA, Tyrer-Cuzick), PENN II requires only a paper and pencil, making it practical for rapid clinic triage.

When to use

• Initial triage in primary care, gynecology, or oncology to identify patients warranting hereditary breast and ovarian cancer (HBOC) genetics referral
• Rapid assessment of BRCA1/2 testing eligibility at first presentation
• Insurance pre-authorization documentation for BRCA1/2 or multigene panel testing
• Screening mammography or oncology clinics without on-site genetic counselors

Formula

Pearls & pitfalls

• Only count BLOOD relatives — bilateral breast cancer in one relative counts as TWO primary cancers if both breasts were separate primaries.
• Ashkenazi Jewish ancestry adds 4 points due to three founder pathogenic variants (BRCA1 185delAG, BRCA1 5382insC, BRCA2 6174delT) with ~2.5% carrier frequency.
• Male breast cancer is heavily weighted (+7) — a single affected male relative is nearly sufficient alone to trigger referral.
• This model assesses probability of BRCA1/2 mutation — NOT the risk of developing cancer. A non-carrier relative with cancer does NOT increase the patient's mutation probability.
• Score < 10 does NOT exclude HBOC — newer multigene panel genes (PALB2, CHEK2, ATM, BRIP1, RAD51C/D) are not assessed by PENN II.
• Validated in mammography (Bellcross 2009), primary care, and oncology populations with sensitivity 85–90% and specificity 40–65% for ≥ 10% mutation probability.
• Consider BOADICEA or Tyrer-Cuzick for more precise quantitative estimates, especially in pedigrees with complex multi-generation history.

Next steps

Score ≥ 10: Refer for formal genetic counseling and consider comprehensive BRCA1/BRCA2 testing or multigene hereditary cancer panel (NCCN Category 1). Score < 10: Patient may still warrant testing per NCCN criteria not captured by PENN II (e.g., triple-negative breast cancer age < 60, Ashkenazi ancestry alone, certain bilateral ovarian patterns). Always apply current NCCN Genetic/Familial High-Risk Guidelines v2.2024 for final determination.

Evidence

Originally developed at the University of Pennsylvania by Armstrong et al. (2000). Validated by Bellcross et al. (Genet Med, 2009) in a mammography population — sensitivity 91%, specificity 45% for ≥ 10% mutation probability. Endorsed as an acceptable HBOC screening tool by NCCN Genetic/Familial High-Risk: Breast, Ovarian, and Pancreatic Guidelines (Category 2A). Compared favorably to BRCAPRO in screening settings due to simplicity.

References

1. Armstrong K et al. Assessing the risk of breast cancer. N Engl J Med. 2000;342(8):564-571. — link
2. Bellcross CA et al. Evaluation of a breast/ovarian cancer genetics referral screening tool in a mammography population. Genet Med. 2009;11(11):783-789. — link
3. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 2.2024. — link